Ardelyx's Tenapanor Selected for Oral and Poster Presentations at the American Society of Nephrology's Kidney Week 2014
FREMONT, Calif., Oct. 23, 2014 /PRNewswire/ -- Ardelyx, Inc.
Positive Top-Line Results Achieved From Two Phase 1 Clinical Trials of BACE Inhibitor BI1181181/VTP-37948 in Alzheimer's Disease
ERYTECH successfully raises €30 million for expanding its therapeutic indications in oncology and accelerating its clinical developments
Forendo Pharma closes EUR 12 million Series A financing round to develop a novel targeted therapy for endometriosis
Novartis AIN457 (secukinumab) meets primary endpoint in two Phase III studies in ankylosing spondylitis, a debilitating joint condition of the spine
Sutro Biopharma and Celgene Corporation Enter Multi-Year Strategic Collaboration and Option to Acquire Agreement
Broad Bi-Specific Antibody Collaboration Now Includes Targets that Could Lead to New Cancer Immunotherapies
A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment History
Johnson & Johnson Announces Major Commitment to Speed Ebola Vaccine Development and Significantly Expand Production
THOUSAND OAKS, Calif., Oct.